federal reserve mit digital currency Related searches

The main contract of Shanghai and Shenzhen 300 stock index futures (IF) fell by 2.00% in the day and is now reported at 3,955.2 points.Shengyi Technology: The total sales volume of the company's rigid copper clad laminate ranks second in the world. Shengyi Technology said at the collective exchange meeting of investors that according to the statistics and ranking of the global rigid copper clad laminate in 2023 by Prismark of the United States, the total sales volume of the company's rigid copper clad laminate ranks second in the world, with a global market share of 14%. Regarding the growth trend of AI server, the company said that the upgrade iteration of hardware equipment related to AI server is fast, and the product form is quite different from that of previous wired products. The company can quickly respond to customer requirements and provide solutions. It is expected that AI applications will gradually develop from large model training to application in the future, and it is expected to achieve good growth.Shanghai Gold Exchange: the settlement price of NYAuTN12 contract in Shanghai New Zealand was 627.85 yuan/gram. On December 13th, Shanghai Gold Exchange issued a notice saying that NYAuTN12 contract in Shanghai New Zealand was settled on December 13th, 2024. The details of the settlement of the contract are as follows: the settlement price of NYAuTN12 contract in Shanghai New Zealand was 627.85 yuan/gram.

Yu Donglai: The goal of Fat Donglai is for employees to take 40 to 60 days off every year, and get more than 8,000 yuan a month. On December 13th, Yu Donglai posted on the social platform that the goal that Fat Donglai will pursue in the next few years is to work within 36 hours a week, close the store on Saturday and rest, so that employees can enjoy the wonderful weekend with their families. During the 40-60-day vacation every year, the minimum monthly net income of employees will remain above 8,000 yuan.Japanese Prime Minister's Assistant: Japan must be prepared for Trump to impose tariffs. Japanese Prime Minister's Assistant Akihisa Nagashima said that Japan needs to be prepared for US President-elect Trump's threat to impose tariffs on China, Canada and Mexico, and adjust the supply chain to reduce the collateral damage suffered by Japanese enterprises. In an interview with the media on Thursday, Akihisa Nagashima said that he had "frank" communication with Trump team members on tariff issues during his recent visit to the United States. "I realized that Japan must be ready for Trump to implement his plan," he said. Akihisa Nagashima said that these tariff measures may encourage Japan to reduce its dependence on these three countries, where some Japanese companies operate and parts made in Japan are transported to these three countries to manufacture finished products for export to the United States. "Japanese companies will certainly try to restructure the supply chain," he pointed out. "This is economically reasonable." (Interface News)Hite Bio: Two drugs are planned to be selected for national centralized drug procurement. Hite Bio announced that the company participated in the tenth batch of national centralized drug procurement. According to the selected results released by the joint procurement, roxatidine acetate hydrochloride and pentoxifylline injection for injection of the company are selected for this centralized procurement. These two drugs are suitable for the treatment of upper gastrointestinal bleeding and peripheral arterial diseases respectively. The procurement cycle is from the date of implementation of the selected results to December 31, 2027, during which medical institutions will give priority to the use of selected drugs. The company obtained the Drug Registration Certificate of the above drugs in 2024, but it has not generated sales revenue this year. This election will help to enhance the brand influence of the company and have a positive impact on the company's development.

Turkish Foreign Minister Fidan discussed the situation in Syria and Gaza with US Secretary of State Blinken. Turkish Foreign Minister Fidan: We discussed the possible roles of Turkey and the United States in Syria in the future. Our primary task is to ensure the stability of Syria and prevent extremist organizations "Islamic State" and the PKK from taking control of Syria.Deputy Director Huang Huabo attended the 2024 annual discussion meeting of members of the National Medical Security Standardization Working Group. On December 12, 2024, the 2024 annual discussion meeting of members of the National Medical Security Standardization Working Group was held in Beijing. Huang Huabo, chairman of the working group, member of the party group and deputy director of the National Health Insurance Bureau, attended and spoke. The symposium summarized the work results of the National Working Group on Medical Security Standardization in 2024, and discussed the work in 2025, the five-year development plan of medical security standardization, the framework system and relevant medical insurance standards. Huang Huabo pointed out that in 2024, with the guidance of the National Standards Committee and the support of the bureau party group, all the work of the working group was smoothly promoted through the joint efforts of all members and relevant units inside and outside the bureau. In 2025, the high-quality development of medical insurance put forward higher requirements for medical insurance standardization. It is necessary to further strengthen the sense of responsibility, professionalism and cooperation, accelerate the construction of medical insurance standardization team, and play a supporting role for the high-quality development of medical insurance. (National Medical Insurance Bureau)Hite Bio: Two drugs are planned to be selected for national centralized drug procurement. Hite Bio announced that the company participated in the tenth batch of national centralized drug procurement. According to the selected results released by the joint procurement, roxatidine acetate hydrochloride and pentoxifylline injection for injection of the company are selected for this centralized procurement. These two drugs are suitable for the treatment of upper gastrointestinal bleeding and peripheral arterial diseases respectively. The procurement cycle is from the date of implementation of the selected results to December 31, 2027, during which medical institutions will give priority to the use of selected drugs. The company obtained the Drug Registration Certificate of the above drugs in 2024, but it has not generated sales revenue this year. This election will help to enhance the brand influence of the company and have a positive impact on the company's development.